Early-stage human trial data on a vaccine being produced by AstraZeneca and the University of Oxford will be published on July 20, medical journal The Lancet said on Wednesday. The vaccine candidate is already undergoing large-scale clinical trials in Phase III to determine whether it can defend against COVID-19, but its developers have yet to announce Phase I results that would show whether it is safe and whether it causes an immune response.
A preclinical shot test in pigs showed that two doses provided a greater response to the antibody than a single dose. More than 100 vaccines are being produced and tested globally to try to stop the COVID-19 pandemic, which has killed hundreds of thousands of people and devastated the global economy. The chief scientist of the World Health Organization said in June that AstraZeneca’s AZD1222 was potentially the developmentally most advanced.
The company has signed deals to supply the vaccine with governments across the globe should it prove successful. Researchers in the United States announced on Tuesday that the experimental vaccine from Moderna Inc proved it was safe and stimulated immune responses in an ongoing early-stage trial in all 45 healthy volunteers.